Fundamental Data for INCY

INCYTE COR(NSDQ:INCY)

Incyte Corp is a drug discovery company that is using its expertise in genomics, medicinal chemistry and molecular, cellular and in vivo biology to discover and develop novel therapeutics. The company has three fully-staffed drug discovery programs underway focused primarily on the identification of new small molecule drugs for cancer and inflammation. Incyte also has strategic alliances with Lexicon Genetics and Medarex focused on the discovery and development of protein therapeutics or antibodies to treat inflammatory diseases and cancer.

# Employees: 212

Address: Route 141 & Henry Clay Road Building E336,Wilmington,DE,USA

Phone: 302 498-6700

Fax: 302-425-2750

Website: www.incyte.com

Email: pmurphy@incyte.com

Sector: Medical

Industry: MED-BIOMED/GENE

Executive Officers

Richard U. Deschutter (Chmn.)

Paul A. Friedman (C.E.O.; Dir.)

David C. Hastings (C.E.O.; Dir.)

Laurent Chardonnet (V.P.; Fin.; Treas.)

Barry M. Ariko (Dir.,)

Dividend

Ex-Dividend Date: N/A

Annual Dividend: N/A

Current Dividend Yield: N/A

Dividend Paid (3 months): N/A

Indicated Dividend: N/A

Earnings

Last Earnings Date: 9/30/2009

Next Earnings Date(Expected): 2/17/2010

Mean EPS (Next Qtr): ($0.38)

Mean EPS (Year): ($1.64)

Mean Estimate(Long Term): ($0.01)

P/E Ratio(Based on EPS estimate): -0.010

Number of Estimates: 11

Shares Performance

Period	INCY	Compare to S&P
YTD	99.21 %	64.87 %
4 Weeks	34.10 %	32.66 %
12 Weeks	11.69 %	5.30 %

Shares Information

Analyst Coverage: Y

Avg Volume: 3292672

Shares Outstanding: 115M

Market Cap: $0.87B

52 Week High: $8.18

52 Week Low: $2.05

P/E Ratio: -0.010

PEG Ratio: -0.010

Split: On 9/1/2000 INCY split by factor of 2.000

Earnings Performance

EPS Growth in Last Quarter: 4.88 %

EPS Growth in Last Year: 18.75 %

Sales Growth in Last Quarter: 19.01 %

Sales Growth in Last Quarter: -11.50 %

Financials

Qtr Book Value: ($0.01)

Cash Flow/Share: ($0.01)

Change in Payout Ratio: -0.010

Price/Sales: 262.040